Understand the source comparison
AOD-9604 Protocol: Age Group Comparison
20s–30s 300mcg 12 weeks 4 weeks Augments existing high-GH tone; selective beta-3 agonism without IGF-1 elevation Best results with lower dose due to intact endogenous GH; higher doses risk rebound lipogenesis 40s 400mcg 14 weeks Compensates for early GH declin
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 20s–30s
- 300mcg
- 12 weeks
- 4 weeks
- Augments existing high-GH tone; selective beta-3 agonism without IGF-1 elevation
- Best results with lower dose due to intact endogenous GH; higher doses risk rebound lipogenesis
- 40s
- 400mcg
- 14 weeks
- Compensates for early GH decline; maintains lipolytic signalling as baseline drops
- Moderate dose increase justified as endogenous GH secretion falls ~15% per decade after 30
- 50s+
- 500mcg
- 16 weeks
- 6 weeks
- Fills significant GH deficit; receptor saturation less likely due to blunted baseline
- Higher dose tolerated well; longer cycles viable because receptor downregulation occurs more slowly